Armistice Capital
Armistice Capital reported 323 stocks worth $3.6B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are MDGL (4.3%), SUPN (3.4%) and CYTK (2.8%). Compared with Q1 2026, the fund opened new positions in WAT, ILMN and PBH, added to MDGL, SUPN and CYTK, trimmed NBIX, TVTX and AGIO and sold out of MDLN, ENR and META.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  MDGL Madrigal Pharmaceuticals Inc | $155M | 4.3% | 288K | +23K (+9%) | 8 of 8 | |
| 2 |  SUPN Supernus Pharmaceuticals Inc | $123M | 3.4% | 2.6M | +751K (+40%) | 8 of 8 | |
| 3 |  CYTK Cytokinetics Inc | $102M | 2.8% | 1.2M | +437K (+57%) | 8 of 8 | |
| 4 |  INCY Incyte Corp | $102M | 2.8% | 900K | +243K (+37%) | 8 of 8 | |
| 5 |  NBIX Neurocrine Biosciences Inc | $90.3M | 2.5% | 536K | −188K (−26%) | 8 of 8 | |
| 6 |  TVTX Travere Therapeutics Inc | $89.3M | 2.5% | 1.6M | −3.3M (−68%) | 8 of 8 | |
| 7 |  AGIO Agios Pharmaceuticals Inc | $89.1M | 2.5% | 2.4M | −316K (−12%) | 8 of 8 | |
| 8 |  PTCT Ptc Therapeutics Inc | $87.4M | 2.4% | 1.1M | −1M (−48%) | 8 of 8 | |
| 9 |  UNH Unitedhealth Group Inc | $76.1M | 2.1% | 183K | +35K (+24%) | 2 of 8 | |
| 10 |  FRPT Freshpet Inc | $74.5M | 2.1% | 1.3M | +167K (+15%) | 7 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
AVANOS MED INC | $28M | 2M |
 MDLN Medline Inc | $25.1M | 565K |
KALVISTA PHARMACEUTICALS INC | $24.9M | 1.2M |
 ENR Energizer Hldgs Inc New | $19.7M | 1.2M |
 META Meta Platforms Inc | $18.6M | 33K |
🔒 Free account: see all 30.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
 SPY Spdr S&P 500 ETF TR | Put | $2.4B | 3.2M | +1,100,000 |
 IWM Ishares TR | Put | $1.7B | 5.8M | +2,300,000 |
CYTK Cytokinetics Inc | Call | $130M | 1.5M | −170,000 |
AGIO Agios Pharmaceuticals Inc | Call | $104M | 2.8M | −390,000 |
PTCT Ptc Therapeutics Inc | Call | $53.8M | 660K | +270,000 |
🔒 Free account: see all 10.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Armistice Capital 13F FAQ
What does Armistice Capital own?
Armistice Capital reported 323 stocks worth $3.6B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are MDGL (4.3%), SUPN (3.4%) and CYTK (2.8%). The table above lists every position in the filing (the top 10 without an account).
What did Armistice Capital buy and sell in Q2 2026?
Compared with Q1 2026: 169 new positions, 70 added to, 64 trimmed and 97 sold out. New positions include WAT, ILMN and PBH. It sold all of MDLN, ENR and META.
When will Armistice Capital file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Armistice Capital's portfolio worth?
The Q2 2026 filing reports $3.6B in US stocks ($8.2B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.